<DOC>
	<DOCNO>NCT02201420</DOCNO>
	<brief_summary>The purpose study ( NAV3-12 ) determine dissemination localization Tc 99m tilmanocept SPECT SPECT/CT image subject confirm cutaneous KS . This single center , open-label , within-subject study .</brief_summary>
	<brief_title>Evaluation Tc 99m Tilmanocept Localization Primary Cutaneous Kaposi 's Sarcoma Lymphatic Drainage SPECT/CT</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>1 . The subject provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization initiation studyrelated procedure . 2 . The subject least 18 year age time consent . 3 . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status Grade 0 2 . 4 . The subject KS stage T ( 0 ) , I ( 0 ) , S ( 0 ) . 5 . The subject marker lesion confirm diagnosis KS ( CD 206expressing cutaneous KS ) via punch biopsy . The location marker KS lesion limit location extremity : shoulder metacarpal region groin metatarsal region . 6 . The subject marker KS lesion â‰¥ 1cm diameter . 1 . The subject pregnant lactating . 2 . The subject prior chemotherapy , immunotherapy , radiation therapy local KS site regional lymphatic system within one year enrollment . 3 . The subject undergone node basin surgery type radiation nodal basin ( ) potentially drain marker KS lesion . 4 . The subject know sensitivity dextran .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>